This presentation contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this presentation should be evaluated together with the many uncertainties that affect Merck's business, particularly those mentioned in the risk factors and cautionary statements in Item 1A of Merck's Form 10-K for the year ended Dec. 31, 2008, and in any risk factors or cautionary statements contained in the Company's periodic reports on Form 10-Q or current reports on Form 8-K, which the Company incorporates by reference.
No Duty to Update

The information contained in the presentation set forth below was current as of October 15, 2009. While this presentation remains on the company’s website the company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the presentation and investors should not rely upon the information as current or accurate after October 15, 2009.
• The chart below reflects the Company’s research pipeline as of October 15, 2009.

• Candidates shown in Phase III include specific products. Candidates shown in Phase I, II and III include the most advanced compound with a specific mechanism in a given therapeutic area. Back-up candidates, regardless of their phase of development, additional claims for in-line products, line extensions, or formulations are not shown.

• This chart has been excerpted from MERCK & CO, INC., form 10-Q filed with the SEC on November 2, 2009 and should be viewed along with disclosures in that filing.
## Merck Pipeline: October 15, 2009

### Phase III
- Atherosclerosis, MK-0524A
- Atherosclerosis, MK-0524B
- Atherosclerosis, MK-0859 (anacetrapib)
- Cancer, MK-8669 (ridaforolimus)
- Diabetes, MK-0431C
- HPV, V503
- Migraine, MK-0974 (telcagepant)
- Ophthalmology, MK-2452 (tafluprost)
- Osteoporosis, MK-0822 (odanacatib)

### Phase II
- Infectious Disease, V419
- Infectious Disease, V710
- Insomnia, MK-4305
- Osteoporosis, MK-5442
- Psychiatric Disease, MK-0594
- Psychiatric Disease, MK-8998
- Respiratory Disease, MK-0476C
- Sarcopenia, MK-2866 (ostarine)

### Phase I
- Alzheimer's Disease, V950
- Cancer, MK-0752
- Cancer, MK-1496
- Cancer, MK-1775
- Cancer, MK-2206
- Cancer, MK-4827
- Cancer, MK-5108
- Cancer, MK-8033
- Cancer, V934/V935
- Cardiovascular, MK-3614
- Diabetes, MK-4074
- Endocrine, MK-4618
- Endocrine, MK-6913
- Infectious Disease, MK-3118
- Infectious Disease, MK-3281
- Infectious Disease, MK-6186
- Infectious Disease, MK-6406
- Infectious Disease, V114
- Neurology, MK-7288
- Neutropenia, MK-4214
- Neutropenia, MK-6302
- Pain, MK-4409
- Psychiatric Disease, MK-8368
- Respiratory Disease, MK-7246
- Anemia, MK-2578
- Atherosclerosis, MK-1903
- Cancer, MK-0646
- Cardiovascular, MK-0736
- Cardiovascular, MK-4448 (bexarotene)
- Cardiovascular, MK-6621 (vernakalant [oral])
- Diabetes, MK-0893
- Diabetes, MK-0941
- Diabetes, MK-8245
- Infectious Disease, MK-315A
- Infectious Disease, MK-7009

### Progressed since July, 2009

- An affiliate of the Company has exclusive rights outside of the United States, Canada and Mexico to vernakalant (IV) for rapid conversion of acute atrial fibrillation to normal heart rhythm. In August, Merck announced that the European Medicines Agency accepted for review the Company’s Marketing Authorization Application for regulatory approval of vernakalant intravenous (IV) in the EU.
- Launched in certain countries in Europe.